Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037)

View/Open

Published version (821.0Kb)

Date

2020-12-01

ICR Author

Folkerd, Elizabeth

Bliss, Judith

Kaye, Stanley Bernard

Dowsett, Mitch

Kilburn, Lucy

Author

Banerjee, S

Tovey, H

Bowen, R

Folkerd, E

Kilburn, L

McLachlan, J

Hall, M

Tunariu, N

Attygalle, A

Lima, JPDSN

Perry, S

Chatfield, P

Hills, M

Kaye, S

Attard, G

Dowsett, M

Bliss, JM

Show allShow less

Type

Journal Article

Metadata

Show full item record

URI

https://repository.icr.ac.uk/handle/internal/4326

DOI

https://doi.org/10.1177/1758835920975352

Collections

• Breast Cancer Research
• Clinical Studies
• Closed Research Teams
• Molecular Pathology

Subject

Science & Technology

Life Sciences & Biomedicine

Oncology

abiraterone

androgen receptor

CYP17 inhibitor

low grade serous

ovarian cancer

Research team

Clinical Trials & Statistics Unit

Medicine Drug Development Unit (Kaye)

Endocrinology

Clinical Trials & Statistics Unit

Medicine Drug Development Unit (Kaye)

Endocrinology

Language

eng

License start date

2020-12-01

Citation

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12 pp. ? - ? (13)

Publisher

SAGE PUBLICATIONS LTD